Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
NCT ID: NCT02961270
Last Updated: 2016-11-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
30 participants
INTERVENTIONAL
2016-11-30
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
icotinib
patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity
Icotinib
Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Icotinib
Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with uncommon epidermal growth factor receptor (EGFR) mutation
* Targeted-therapy-naive patients
* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
* Evaluable target lesions according to RECIST 1.1 for tumour response assessment
Exclusion Criteria
* Positive 19 del and/or 21 L858R mutation
* Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib
* Patients who have documented history of interstitial lung disease
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shengyu Zhou
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shengyu Zhou, MD
Role: STUDY_CHAIR
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shengyu Zhou, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAMS-ZH-001
Identifier Type: -
Identifier Source: org_study_id